U.S. Consumer Durables Stock News

Aon (NYSE:AON) is back in focus after expanding its Data Center Lifecycle Insurance Program by an additional $1 billion, lifting total capacity to $3.5 billion and extending coverage to existing post-commissioning data centers. See our latest analysis for Aon. Aon’s recent product and dividend announcements come after a mixed period for investors, with the share price at $331.95 and a 30 day share price return of 1.94%, against a year to date share price decline of 3.58% and a 1 year total...

The United States market has shown robust performance, climbing 3.6% in the last week and 39% over the past year, with earnings projected to grow by 16% annually. In this thriving environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.

Over the last 7 days, the United States market has risen 3.6%, and over the past year, it has climbed 39%, with earnings expected to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, these stocks can present an underappreciated chance for stability and potential upside in today's market conditions.

In the past week, Griffon reported quarterly results with revenues and adjusted operating income coming in ahead of analyst expectations, even as full-year revenue guidance fell short of consensus and lagged peers. The contrast between a stronger-than-expected quarter and relatively soft guidance has sharpened attention on how much of Griffon’s recent strength is sustainable versus cyclical. With Griffon’s recent revenue beat but softer full-year outlook, we’ll examine how this mixed...

Recent performance snapshot Zurn Elkay Water Solutions (ZWS) has attracted investor attention following a period in which the stock posted a modest one-day move, weaker performance over the past week, and positive returns over the past month and past three months. See our latest analysis for Zurn Elkay Water Solutions. At a share price of $47.78, Zurn Elkay Water Solutions has recently paired a weaker 7 day share price return with a stronger 1 month share price return, while its 1 year total...

10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open and shipments targeted for the second half of 2026. Early Atera data from leading groups like the June Lab and the German Cancer Research Center suggest the platform can reveal previously hidden tumor–immune interactions that may reshape research and drug discovery approaches. We’ll now examine...

Under Armour (UAA) is back in the spotlight after Unrivaled Sports announced new partnerships with the brand and DICK'S Sporting Goods, focused on youth sports programming nationwide and exclusive apparel roles at marquee events. See our latest analysis for Under Armour. Investors have seen momentum build recently, with a 7 day share price return of 7.65% and a 30 day share price return of 12.99%. At the same time, the 1 year total shareholder return of 15.16% contrasts with a 5 year total...

Donnelley Financial Solutions (DFIN) drew renewed attention to its stock after authorizing a new share repurchase program of up to $150 million, running through December 31, 2027, alongside updates on recent buyback activity. See our latest analysis for Donnelley Financial Solutions. The buyback announcement and recent repurchases come at a time when the share price is US$52.53, with a 7 day share price return of 7.40% and a 30 day share price return of 13.02%. The 1 year total shareholder...

MACOM Technology Solutions Holdings (MTSI) has drawn fresh attention after introducing 448G PAM4 modulator drivers designed for 1.6T and 3.2T optical transceivers, directly tying the business to high speed AI data center networking. See our latest analysis for MACOM Technology Solutions Holdings. The recent 448G PAM4 launch comes as momentum in MACOM's share price has been strong, with a 60.65% year to date share price return and a very large 1 year total shareholder return. This indicates...

Morgan Stanley recently elevated Affirm Holdings to its Top Pick list, arguing that concerns around private credit are too pessimistic and pointing to upcoming company updates on gross merchandise volume, margins, and long-term earnings targets at its May Investor Forum as important reference points. An interesting angle is Morgan Stanley’s expectation that Affirm will outline a fiscal 2028 GAAP EPS range that the bank views as conservative, potentially reframing how investors think about...

The United States market has experienced a notable upswing, climbing 3.6% over the last week and an impressive 39% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to capitalize on market momentum while discovering potential value.

Event overview and recent stock performance Ladder Capital (LADR) has attracted fresh attention after recent share moves, with the stock showing a 5.3% gain over the past month but a 7% decline over the past 3 months. See our latest analysis for Ladder Capital. Zooming out, Ladder Capital’s share price return has softened year to date, with a 7.3% decline. However, the 1 year total shareholder return of 12.2% and 3 year total shareholder return of 44.2% indicate a constructive longer term...

What recent performance says about East West Bancorp East West Bancorp (EWBC) has drawn attention after a strong month, with the stock showing a 15% return and a gain of about 6% over the past 3 months. This recent performance has prompted some investors to reassess its valuation. See our latest analysis for East West Bancorp. Putting that move in context, the 15.0% 1 month share price return sits alongside a 3.5% year to date share price return and a 60.2% 1 year total shareholder return...

Setting the scene on Cboe Global Markets (CBOE) Cboe Global Markets (CBOE) has drawn fresh attention after the stock’s recent move, with investors weighing its current valuation against trading performance across options, equities, futures, and FX platforms. With a last close of $304.40 and a market cap of about $31.4b, Cboe’s recent returns over the past month and past 3 months are prompting closer scrutiny of how its diverse revenue streams support that pricing. See our latest analysis for...

Broadcom (AVGO) is back in focus after reports that Google may add Marvell as a custom AI chip partner, raising questions about how competition and supplier diversification could influence the stock’s recent strong run. See our latest analysis for Broadcom. The latest 1 day share price decline of 1.70% to US$399.63 comes after reports of Google talking to Marvell, but that pullback sits against a 30 day share price return of 28.70% and a very strong 1 year total shareholder return of 142.39%,...

Recently, Citigroup cut its rating on Insulet Corporation to Neutral, citing rising competition in the patch insulin pump market and the potential impact of rival devices expected to arrive in 2027. At the same time, Insulet appointed Mike Panos as Executive Vice President and Chief Commercial Officer, highlighting the company’s focus on strengthening global commercialization of its Omnipod platform despite a more crowded competitive landscape. Next, we’ll examine how Citigroup’s downgrade,...

Aehr Test Systems overview and recent performance context Aehr Test Systems (AEHR) has drawn attention after a sharp move in its share price, with the stock showing strong returns over the past month, past 3 months and year to date. For context, Aehr Test Systems focuses on designing, manufacturing and marketing advanced test and burn in products used across silicon carbide power devices, sensors, memory and other semiconductor applications. Its market value stands at about US$2.64b, with...

Royal Caribbean Cruises (RCL) has been back on investors’ radar after its stock rallied when Iran temporarily reopened the Strait of Hormuz, easing supply concerns, along with upbeat commentary on the company’s use of artificial intelligence. See our latest analysis for Royal Caribbean Cruises. Beyond the latest geopolitical and AI headlines, Royal Caribbean’s share price has had a mixed few months, with a 7.06% 1 month share price return and a 51.14% 1 year total shareholder return that...

In April 2026, Marsh & McLennan Companies reported first-quarter 2026 results showing sales of US$7,597 million, net income of US$1,146 million, and lower earnings per share year over year, alongside confirmation that it completed a US$1,074.65 million buyback covering 1.23% of shares since November 2025. While revenue increased compared with the prior year, the combination of declining net income and earnings per share with continued share repurchases highlights a shift in the balance...

Praxis Precision Medicines recently reported that the FDA accepted its New Drug Application for ulixacaltamide HCl to treat adult essential tremor, supported by statistically and clinically significant Phase 3 Essential3 data and prior Breakthrough Therapy Designation. This regulatory milestone, with a PDUFA action date set for January 29, 2027 and no planned advisory committee, could reshape expectations for Praxis’s central nervous system portfolio alongside its epilepsy programs. Next,...

Ingles Markets (IMKT.A) is in the middle of a high profile proxy fight after issuing open letters urging shareholders to back its nominees instead of activist-backed candidate Rory Held, as governance and conflict concerns take center stage. See our latest analysis for Ingles Markets. At a share price of US$88.11, Ingles Markets has seen a 25.10% 90 day share price return and a 26.47% year to date share price return. The 1 year total shareholder return of 39.65% contrasts with a 3 year total...

GRAIL (GRAL) stock is drawing attention after back to back announcements that extend access to its Galleri multi cancer early detection blood test through Epic’s electronic health record platform and Junction’s digital health infrastructure. See our latest analysis for GRAIL. Investors appear to be weighing these new distribution partnerships against a tougher recent trading history, with the share price at US$51.20, a 7 day share price return of 6.6% and a 90 day share price return showing a...

Cedar Grove Capital Management’s latest Q1 2026 investor letter put RealReal (REAL) in focus, pointing to its role in the fast growing second hand luxury market and recent operational and profitability metrics. See our latest analysis for RealReal. RealReal’s share price has been volatile, with a 36.9% 1 month share price return and a 25.1% decline year to date, while 1 year total shareholder return is 124.5%. If this kind of rebound catches your eye, it could be worth broadening your...

Earlier this month, Ultragenyx Pharmaceutical reported that the US FDA accepted its resubmitted Biologics License Application for UX111, an investigational AAV9 gene therapy for Sanfilippo syndrome Type A, and set a PDUFA action date of 19 September. If UX111 is ultimately approved, it could become the first available treatment for this rare, fatal pediatric neurodegenerative disorder, marking a potentially important expansion of Ultragenyx’s rare-disease gene therapy portfolio. We’ll now...